A quantitative review of the postmortem evidence for decreased cortical N-methyl-d-aspartate receptor expression levels in schizophrenia: How can we link molecular abnormalities to mismatch negativity deficits?

Biological Psychology

Volumn 116, Issue , 2016, Pages 57-67

  Catts, Vibeke S ^a,b,c   Lai, Yan Ling ^b,c   Weickert, Cyndi Shannon ^a,b,c   Weickert, Thomas W ^a,b,c   Catts, Stanley V ^b,d,e  

^a SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Glutamate; Meta analysis; Mismatch negativity; NMDA receptor; Prefrontal cortex; Schizophrenia

Indexed keywords

MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ARTICLE; AUTOPSY; BRAIN CORTEX; BRAIN LEVEL; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; MISMATCH NEGATIVITY; MISMATCH NEGATIVITY DEFICIT; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; SOMATOSENSORY DISORDER; ANIMAL; ANIMAL MODEL; AUDITORY EVOKED POTENTIAL; GENE EXPRESSION; GENETICS; META ANALYSIS; METABOLISM; PATHOPHYSIOLOGY; PREFRONTAL CORTEX;

ANIMALS; AUTOPSY; EVOKED POTENTIALS, AUDITORY; GENE EXPRESSION; HUMANS; MODELS, ANIMAL; PREFRONTAL CORTEX; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 84961399506     PISSN: 03010511     EISSN: 18736246     Source Type: Journal    
DOI: 10.1016/j.biopsycho.2015.10.013     Document Type: Article

References (150)

1. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. Journal of Neuroscience 1996, 16:19-30.
2. Alho K. Cerebral generators of mismatch negativity (MMN) and its magnetic counterpart (MMNM) elicited by sound changes. Ear and Hearing 1995, 16:38-51.
3. Andreou C., Nolte G., Leicht G., Polomac N., Hanganu-Opatz I.L., Lambert M., et al. Increased resting-state gamma-band connectivity in first-episode schizophrenia. Schizophrenia Bulletin 2015, 41:930-939.
4. Anticevic A., Corlett P.R., Cole M.W., Savic A., Gancsos M., Tang Y., et al. N-methyl-d-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia. Biol. Psychiatry 2015, 77:569-580.
5. Atkinson R.J., Michie P.T., Schall U. Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis. Biol. Psychiatry 2012, 71:98-104.
6. Bai G., Norton D.D., Prenger M.S., Kusiak J.W. Single-stranded DNA-binding proteins and neuron-restrictive silencer factor participate in cell-specific transcriptional control of the NMDAR1 gene. Journal of Biological Chemistry 1998, 273:1086-1091.
7. Baldeweg T., Hirsch S.R. Mismatch negativity indexes illness-specific impairments of cortical plasticity in schizophrenia: a comparison with bipolar disorder and Alzheimer's disease. International Journal of Psychophysiology 2015, 95:145-155.
8. Baldeweg T., Klugman A., Gruzelier J., Hirsch S.R. Mismatch negativity potentials and cognitive impairment in schizophrenia. Schizophrenia Research 2004, 69:203-217.
9. Ballesteros A., Summerfelt A., Du X.M., Jiang P., Chiappelli J., Tagamets M., et al. Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clinical Neurophysiology 2013, 124:2209-2215.
10. Balu D.T., Li Y., Puhl M.D., Benneyworth M.A., Basu A.C., Takagi S., et al. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:E2400-E2409.
11. Beasley C.L., Reynolds G.P. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophrenia Research 1997, 24:349-355.
12. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., Meador-Woodruff J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007, 32:1888-1902.
13. Beneyto M., Meador-Woodruff J.H. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008, 33:2175-2186.
14. Billingslea E.N., Tatard-Leitman V.M., Anguiano J., Jutzeler C.R., Suh J., Saunders J.A., et al. Parvalbumin cell ablation of NMDA-RI causes increased resting network excitability with associated social and self-care deficits. Neuropsychopharmacology 2014, 39:1603-1613.
15. Blatow M., Rozov A., Katona I., Hormuzdi S.G., Meyer A.H., Whittington M.A., et al. A novel network of multipolar bursting interneurons generates theta frequency oscillations in neocortex. Neuron 2003, 38:805-817.
16. Bodatsch M., Brockhaus-Dumke A., Klosterkotter J., Ruhrmann S. Forecasting psychosis by event-related potentials-systematic review and specific meta-analysis. Biol. Psychiatry 2015, 77:951-958.
17. Cardin J.A., Carlen M., Meletis K., Knoblich U., Zhang F., Deisseroth K., et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature 2009, 459:663-667.
18. Carlen M., Meletis K., Siegle J.H., Cardin J.A., Futai K., Vierling-Claassen D., et al. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Molecular Psychiatry 2012, 17:537-548.
19. Carpenter W.T., Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Heresco-Levy U., et al. Testing two efficacy hypotheses for the treatment of negative symptoms. Schizophrenia Bulletin 2005, 31. 478.
20. Carracedo L.M., Kjeldsen H., Cunnington L., Jenkins A., Schofield I., Cunningham M.O., et al. A neocortical delta rhythm facilitates reciprocal interlaminar interactions via nested theta rhythms. Journal of Neuroscience 2013, 33:10750-10761.
21. Catts S.V., Shelley A.M., Ward P.B., Liebert B., McConaghy N., Andrews S., et al. Brain potential evidence for an auditory sensory memory deficit in schizophrenia. American Journal of Psychiatry 1995, 152:213-219.
22. Catts V., Catts S. The psychotomimetic effects of PCP, LSD and ecstacy: pharmacological models of schizophrenia?. Secondary schizophrenia 2010, Cambridge University Press, Cambridge. P. Sachdev, M. Keshavan (Eds.).
23. Catts V.S., Derminio D.S., Hahn C.G., Shannon Weickert C. Postsynaptic density levels of the NMDA receptor NR1 subunit and PSD-95 protein in prefrontal cortex from people with schizophrenia. NPJ Schizophrenia 2015, 1. 15307.
24. Catts V.S., Fung S.J., Long L.E., Joshi D., Vercammen A., Allen K.M., et al. Rethinking schizophrenia in the context of normal neurodevelopment. Frontiers in Cellular Neuroscience 2013, 7.
25. Chatterton J.E., Awobuluyi M., Premkumar L.S., Takahashi H., Talantova M., Shin Y., et al. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature 2002, 415:793-798.
26. Choi K.H., Zepp M.E., Higgs B.W., Weickert C.S., Webster M.J. Expression profiles of schizophrenia susceptibility genes during human prefrontal cortical development. Journal of Psychiatry & Neuroscience 2009, 34:450-458.
27. Clarke R.J., Johnson J.W. NMDA receptor NR2 subunit dependence of the slow component of magnesium unblock. Journal of Neuroscience 2006, 26:5825-5834.
28. Cochran S.M., Kennedy M., McKerchar C.E., Steward L.J., Pratt J.A., Morris B.J. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 2003, 28:265-275.
29. Cotter D., Landau S., Beasley C., Stevenson R., Chana G., MacMillan L., et al. The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol. Psychiatry 2002, 51:377-386.
30. Crair M.C., Malenka R.C. A critical period for long-term potentiation at thalamocortical synapses. Nature 1995, 375:325-328.
31. Dalmau J., Lancaster E., Martinez-Hernandez E., Rosenfeld M.R., Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurology 2011, 10:63-74.
32. Dalmau J., Tuzun E., Wu H.Y., Masjuan J., Rossi J.E., Voloschin A., et al. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Annals of Neurology 2007, 61:25-36.
33. Daviss S.R., Lewis D.A. Local circuit neurons of the prefrontal cortex in schizophrenia: selective increase in the density of calbindin-immunoreactive neurons. Psychiatry Research 1995, 59:81-96.
34. Dima D., Frangou S., Burge L., Braeutigam S., James A.C. Abnormal intrinsic and extrinsic connectivity within the magnetic mismatch negativity brain network in schizophrenia: a preliminary study. Schizophrenia Research 2012, 135:23-27.
35. Dracheva S., Marras S.A.E., Elhakem S.L., Kramer F.R., Davis K.L., Haroutunian V. N-methyl-d-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. American Journal of Psychiatry 2001, 158:1400-1410.
36. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Research 1998, 812:65-75.
37. Ehrlichman R.S., Maxwell C.R., Majumdar S., Siegel S.J. Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice. Journal of Cognitive Neuroscience 2008, 20:1403-1414.
38. Emamian E.S., Karayiorgou M., Gogos J.A. Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with schizophrenia. Journal of Neuroscience 2004, 24:1561-1564.
39. Errico F., Napolitano F., Squillace M., Vitucci D., Blasi G., de Bartolomeis A., et al. Decreased levels of d-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia. Journal of Psychiatric Research 2013, 47:1432-1437.
40. Fauman M.A., Fauman B. The psychiatric aspects of chronic phencycldine use: a study of chronic PCP users. Phencyclidine (PCP) abuse: an appraisal 1978, Vol. 21:183-200. National Institute on Drug Abuse, Rockville, Maryland.
41. Featherstone R.E., McMullen M.F., Ward K.R., Bang J., Xiao J., Siegel S.J., et al. EEG biomarkers of target engagement, therapeutic effect, and disease process. Translational Neuroscience in Psychiatry 2015, 1344:12-26.
42. Featherstone R.E., Shin R., Kogan J.H., Liang Y.L., Matsumoto M., Siegel S.J. Mice with subtle reduction of NMDA NR1 receptor subunit expression have a selective decrease in mismatch negativity: implications for schizophrenia prodromal population. Neurobiology of Disease 2015, 73:289-295.
43. Friston K.J., Frith C.D. Schizophrenia-a disconnection syndrome. Clinical Neuroscience 1995, 3:89-97.
44. Fromer M., Pocklington A.J., Kavanagh D.H., Williams H.J., Dwyer S., Gormley P., et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014, 506:179-184.
45. Fuentemilla L., Marco-Pallares J., Munte T.F., Grau C. Theta EEG oscillatory activity and auditory change detection. Brain Research 2008, 1220:93-101.
46. Fulham W.R., Michie P.T., Ward P.B., Rasser P.E., Todd J., Johnston P.J., et al. Mismatch negativity in recent-onset and chronic schizophrenia: a current source density analysis. Public Library of Science 2014, 9.
47. Fung S.J., Fillman S.G., Webster M.J., Weickert C.S. Schizophrenia and bipolar disorder show both common and distinct changes in cortical interneuron markers. Schizophrenia Research 2014, 155:26-30.
48. Fung S.J., Webster M.J., Sivagnanasundaram S., Duncan C., Elashoff M., Weickert C.S. Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. American Journal of Psychiatry 2010, 167:1479-1488.
49. Gaebler A.J., Mathiak K., Koten J.W., Konig A.A., Koush Y., Weyer D., et al. Auditory mismatch impairments are characterized by core neural dysfunctions in schizophrenia. Brain 2015, 138:1410-1423.
50. Gil-Da-Costa R., Stoner G.R., Fung R., Albright T.D. Nonhuman primate model of schizophrenia using a noninvasive EEG method. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:15425-15430.
51. Gonzalez-Burgos G., Lewis D.A. GABA neurons and the mechanisms of network oscillations: Implications for understanding cortical dysfunction in schizophrenia. Schizophrenia Bulletin 2008, 34:944-961.
52. Gordon J.A. Testing the glutamate hypothesis of schizophrenia. Nature Neuroscience 2010, 13:2-4.
53. Gupta C.N., Calhoun V.D., Rachakonda S., Chen J., Patel V., Liu J., et al. Patterns of gray matter abnormalities in schizophrenia based on an international mega-analysis. Schizophrenia Bulletin 2015, 41:1133-1142.
54. Haenschel C., Baldeweg T., Croft R.J., Whittington M., Gruzelier J. Gamma and beta frequency oscillations in response to novel auditory stimuli: a comparison of human electroencephalogram (EEG) data with in vitro models. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:7645-7650.
55. Hahn C.G., Wang H.Y., Cho D.S., Talbot K., Gur R.E., Berrettini W.H., et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nature Medicine 2006, 12:824-828.
56. Harms L. Mismatch responses and deviance detection in N-methyl-d-aspartate (NMDA) receptor hypofunction and developmental models of schizophrenia. Biological Psychology 2016, 116:75-81.
57. Harms L., Michie P.T., Naatanen R. Criteria for determining whether mismatch responses exist in animal models: focus on rodents. Biological Psychology 2016, 116:28-35.
58. Hashimoto T., Arion D., Unger T., Maldonado-Aviles J.G., Morris H.M., Volk D.W., et al. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Molecular Psychiatry 2008, 13:147-161.
59. Hashimoto T., Bazmi H.H., Mirnics K., Wu Q., Sampson A.R., Lewis D.A. Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. American Journal of Psychiatry 2008, 165:479-489.
60. Hay R.A., Roach B.J., Srihari V.H., Woods S.W., Ford J.M., Mathalon D.H. Equivalent mismatch negativity deficits across deviant types in early illness schizophrenia-spectrum patients. Biological Psychology 2015, 105:130-137.
61. Henson M.A., Roberts A.C., Salimi K., Vadlamudi S., Hamer R.M., Gilmore J.H., et al. Developmental regulation of the NMDA receptor subunits, NR3A and NR1, in human prefrontal cortex. Cerebral Cortex 2008, 18:2560-2573.
62. Hertzman M., Reba R.C., Kotlyarov E.V. Single photon-emission computed-tomography in phencycldine and related drug-abuse. American Journal of Psychiatry 1990, 147:255-256.
63. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. Journal of Neuroscience 2007, 27:11496-11500.
64. Hu, W., MacDonald, M.L., Elswick, D.E., Sweet, R.A., 2015. The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies, In: Geschwind, D.H. (Ed.), Year in neurology and psychiatry, Vol. 1338, pp. 38-57.
65. Javitt D.C. Neurophysiological models for new treatment development in schizophrenia: early sensory approaches. Translational Neuroscience in Psychiatry 2015, 1344:92-104.
66. Javitt D.C., Steinschneider M., Schroeder C.E., Arezzo J.C. Role of cortical N-methyl-d-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:11962-11967.
67. Javitt D.C., Steinschneider M., Schroeder C.E., Vaughan H.G., Arezzo J.C. Detection of stimulus deviance within primate auditory cortex-intracortical mechanisms of mismatch negativity (MMN) generation. Brain Research 1994, 667:192-200.
68. Javitt D.C., Strous R.D., Grochowski S., Ritter W., Cowan N. Impaired precision, but normal retention, of auditory sensory (echoic) memory information in schizophrenia. Journal of Abnormal Psychology 1997, 106:315-324.
69. Javitt D.C., Sweet R.A. Auditory dysfunction in schizophrenia: integrating clinical and basic features. Nature Reviews Neuroscience 2015, 16:535-550.
70. Joshi D., Catts V.S., Olaya J.C., Shannon Weickert C. Relationship between somatostatin and death receptor expression in the orbital frontal cortex in schizophrenia: a postmortem brain mRNA study. NPJ Schizophrenia 2015, 1:14004.
71. Karavanova I., Vasudevan K., Cheng J., Buonanno A. Novel regional and developmental NMDA receptor expression patterns uncovered in NR2C subunit-beta-galactosidase knock-in mice. Molecular and Cellular Neuroscience 2007, 34:468-480.
72. Kaser M., Soltesz F., Lawrence P., Miller S., Dodds C., Croft R., et al. Oscillatory underpinnings of mismatch negativity and their relationship with cognitive function in patients with schizophrenia. Public Library of Science 2013, 8.
73. Kaur M., Battisti R.A., Ward P.B., Ahmed A., Hickie I.B., Hermens D.F. MMN/P3a deficits in first episode psychosis: comparing schizophrenia-spectrum and affective-spectrum subgroups. Schizophrenia Research 2011, 130:203-209.
74. Kawakubo Y., Kasai K., Kudo N., Rogers M.A., Nakagome K., et al. Phonetic mismatch negativity predicts verbal memory deficits in schizophrenia. Neuroreport 2006, 17:1043-1046.
75. Kiang M., Light G.A., Prugh J., Coulson S., Braff D.L., Kutas M. Cognitive, neurophysiological, and functional correlates of proverb interpretation abnormalities in schizophrenia. Journal of the International Neuropsychological Society 2007, 13:653-663.
76. Kinon B.J., Millen B.A., Zhang L., McKinzie D.L. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol. Psychiatry 2015, 78:754-762.
77. Kirli K.K., Ermentrout G.B., Cho R.Y. Computational study of NMDA conductance and cortical oscillations in schizophrenia. Frontiers in Computational Neuroscience 2014, 8.
78. Kirov G., Pocklington A.J., Holmans P., Ivanov D., Ikeda M., Ruderfer D., et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Molecular Psychiatry 2012, 17:142-153.
79. Ko D., Kwon S., Lee G.T., Im C.H., Kim K.H., Jung K.Y. Theta oscillation related to the auditory discrimination process in mismatch negativity: oddball versus control paradigm. Journal of Clinical Neurology 2012, 8:35-42.
80. Korostenskaja M., Dapsys K., Siurkute A., Maciulis V., Ruksenas O., Kahkonen S. Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2005, 29:543-548.
81. Korotkova T., Fuchs E.C., Ponomarenko A., von Engelhardt J., Monyer H. NMDA Receptor ablation on parvalbumin-positive interneurons impairs hippocampal synchrony, spatial representations, and working memory. Neuron 2010, 68:557-569.
82. Kotermanski S.E., Johnson J.W. Mg2+ Imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine. Journal of Neuroscience 2009, 29:2774-2779.
83. Kreitschmann-Andermahr I., Rosburg T., Demme U., Gaser E., Nowak H., Sauer H. Effect of ketamine on the neuromagnetic mismatch field in healthy humans. Cognitive Brain Research 2001, 12:109-116.
84. Kristiansen L.V., Beneyto M., Haroutunian V., Meador-Woodruff J.H. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Molecular Psychiatry 2006, 11:737-747.
85. Kristiansen L.V., Patel S.A., Haroutunian V., Meador-Woodruff J.H. Expression of the NR2B-NMDA receptor subunit and its Tbr-1/CINAP regulatory proteins in postmortem brain suggest altered receptor processing in schizophrenia. Synapse 2010, 64:495-502.
86. Law A.J., Weickert C.S., Webster M.J., Herman M.M., Kleinman J.E., Harrison P.J. Expression of NMDA receptor NR1, NR2A and NR2B subunit mRNAs during development of the human hippocampal formation. European Journal of Neuroscience 2003, 18:1197-1205.
87. Le Corre S., Harper C.G., Lopez P., Ward P., Catts S. Increased levels of expression of an NMDARI splice variant in the superior temporal gyrus in schizophrenia. Neuroreport 2000, 11:983-986.
88. Lewis D.A. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Research Reviews 2000, 31:270-276.
89. Lewis D.A. Cortical circuit dysfunction and cognitive deficits in schizophrenia-implications for preemptive interventions. European Journal of Neuroscience 2012, 35:1871-1878.
90. Light G.A., Braff D.L. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Archives of General Psychiatry 2005, 62:127-136.
91. Light G.A., Naatanen R. Mismatch negativity is a breakthrough biomarker for understanding and treating psychotic disorders. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:15175-15176.
92. Liu Y., Liang M., Zhou Y., He Y., Hao Y.H., Song M., et al. Disrupted small-world networks in schizophrenia. Brain 2008, 131:945-961.
93. Low C.M., Wee K.S.L. New insights into the Not-So-New NR3 subunits of N-methyl-d-aspartate receptor: localization, structure, and function. Molecular Pharmacology 2010, 78:1-11.
94. Luisada P.V. The phencyclidine psychosis: phenomenology and treatment. Phencyclidine (PCP) abuse: an appraisal 1978, Vol. 21:241-253. National Institute on Drug Abuse, Rockville, Maryland.
95. March L., Cienfuegos A., Goldbloom L., Ritter W., Cowan N., Javitt D.C. Normal time course of auditory recognition in schizophrenia, despite impaired precision of the auditory sensory (echoic) memory code. Journal of Abnormal Psychology 1999, 108:69-75.
96. Marin O. Interneuron dysfunction in psychiatric disorders. Nature Reviews Neuroscience 2012, 13:107-120.
97. Marsman A., van den Heuvel M.P., Klomp D.W.J., Kahn R.S., Luijten P.R., Pol H.E.H. Glutamate in schizophrenia: a focused review and meta-analysis of H-1-MRS studies. Schizophrenia Bulletin 2013, 39:120-129.
98. Martucci L., Wong A.H.C., De Luca V., Likhodi O., Wong G.W.H., King N., et al. N-methyl-d-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: polymorphisms and mRNA levels. Schizophrenia Research 2006, 84:214-221.
99. Michie P.T., Budd T.W., Todd J., Rock D., Wichmann H., Box J., et al. Duration and frequency mismatch negativity in schizophrenia. Clinical Neurophysiology 2000, 111:1054-1065.
100. Miyanishi T., Sumiyoshi T., Higuchi Y., Seo T., Suzuki M. LORETA current source density for duration mismatch negativity and neuropsychological assessment in early schizophrenia. Public Library Of Science 2013, 8.
101. Moghaddam B., Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012, 37:4-15.
102. Monyer H., Burnashev N., Laurie D.J., Sakmann B., Seeburg P.H. Development and regional expression in the rat brain and functional properties of 4 NMDA receptors. Neuron 1994, 12:529-540.
103. Morris H.M., Hashimoto T., Lewis D.A. Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cerebral Cortex 2008, 18:1575-1587.
104. Moscato E.H., Peng X.Y., Jain A., Parsons T.D., Dalmau J., Balice-Gordon R.J. Acute mechanisms underlying antibody effects in Anti-N-Methyl-d-aspartate receptor encephalitis. Annals of Neurology 2014, 76:108-119.
105. Mothet J.P., Le Bail M., Billard J.M. Time and space profiling of NMDA receptor co-agonist functions. Journal of Neurochemistry 2015, 135:210-225.
106. Mueller H.T., Meador-Woodruff J.H. NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophrenia Research 2004, 71:361-370.
107. Naatanen R. Mismatch negativity (MMN) as an index of central auditory system plasticity. International Journal of Audiology 2008, 47:S16-S20.
108. Naatanen R., Jacobsen T., Winkler I. Memory-based or afferent processes in mismatch negativity (MMN): a review of the evidence. Psychophysiology 2005, 42:25-32.
109. Naatanen R., Kujala T., Kreegipuu K., Carlson S., Escera C., Baldeweg T., et al. The mismatch negativity: an index of cognitive decline in neuropsychiatric and neurological diseases and in ageing. Brain 2011, 134:3432-3450.
110. Naatanen R., Kujala T., Winkler I. Auditory processing that leads to conscious perception: a unique window to central auditory processing opened by the mismatch negativity and related responses. Psychophysiology 2011, 48:4-22.
111. Naatanen R., Shiga T., Asano S., Yabe H. Mismatch negativity (MMN) deficiency: a break-through biomarker in predicting psychosis onset. International Journal of Psychophysiology 2015, 95:338-344.
112. Nagai T., Tada M., Kirihara K., Yahata N., Hashimoto R., Araki T., et al. Auditory mismatch negativity and P3a in response to duration and frequency changes in the early stages of psychosis. Schizophrenia Research 2013, 150:547-554.
113. Nicol R.M., Chapman S.C., Vertes P.E., Nathan P.J., Smith M.L., Shtyrov Y., et al. Fast reconfiguration of high-frequency brain networks in response to surprising changes in auditory input. Journal of Neurophysiology 2012, 107:1421-1430.
114. Nyiri G., Stephenson F.A., Freund T.F., Somogyi P. Large variability in synaptic N-methyl-d-aspartate receptor density on interneurons and a comparison with pyramidal-cell spines in the rat hippocampus. Neuroscience 2003, 119:347-363.
115. O'Donnell B.F., Vohs J.H., Krishnan G.P., Rass O., Hetrick W.P., Morzorati S.L. The auditory steady-state response (ASSR): a translational biomarker for schizophrenia. Supplements to Clinical Neurophysiology 2013, 62:101-112.
116. Okamoto S., Sherman K., Lipton S.A. Absence of binding activity of neuron-restrictive silencer factor is necessary, but not sufficient for transcription of NMDA receptor subunit type 1 in neuronal cells. Molecular Brain Research 1999, 74:44-54.
117. Pearlson G.D. Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. Johns Hopkins Medical Journal 1981, 148:25-33.
118. Peterson R.C., Stillman R.C. Phencyclidine: an overview. Phencycldine (PCP) abuse: an appraisal 1978, Vol. 21:1-17. National Institute on Drug Abuse, Rockville, Maryland.
119. Purcell S.M., Moran J.L., Fromer M., Ruderfer D., Solovieff N., Roussos P., et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 2014, 506:185-190.
120. Rasser P.E., Schall U., Todd J., Michie P.T., Ward P.B., Johnston P., et al. Gray matter deficits, mismatch negativity, and outcomes in schizophrenia. Schizophrenia Bulletin 2011, 37:131-140.
121. Ripke S., Neale B.M., Corvin A., Walters J.T.R., Farh K.H., Holmans P.A., et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511:421-427.
122. Rissling A.J., Miyakoshi M., Sugar C.A., Braff D.L., Makeig S., Light G.A. Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia. Neuroimage-Clinical 2014, 6:424-437.
123. Rowland L.M., Bustillo J.R., Mullins P.G., Jung R.E., Lenroot R., Landgraf E., et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: A 4-T proton MRS study. American Journal of Psychiatry 2005, 162:394-396.
124. Salisbury D.F., Kuroki N., Kasai K., Shenton M.E., McCarley R.W. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Archives of General Psychiatry 2007, 64:521-529.
125. Salisbury D.F., Shenton M.E., Griggs C.B., Bonner-Jackson A., McCarley R.W. Mismatch negativity in chronic schizophrenia and first-episode schizophrenia. Archives of General Psychiatry 2002, 59:686-694.
126. Schmidt A., Diaconescu A.O., Kometer M., Friston K.J., Stephan K.E., Vollenweider F.X. Modeling ketamine effects on synaptic plasticity during the mismatch negativity. Cerebral Cortex 2013, 23:2394-2406.
127. Shelton M.A., Newman J.T., Gu H., Sampson A.R., Fish K.N., MacDonald M.L., et al. Loss of microtubule-associated protein 2 immunoreactivity linked to dendritic spine loss in schizophrenia. Biol. Psychiatry 2015, 78:374-385.
128. Sivarao D.V. The 40-Hz auditory steady-state response: a selective biomarker for cortical NMDA function. Translational Neuroscience in Psychiatry 2015, 1344:27-36.
129. Sokolov B.P. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of neuroleptic-free schizophrenics: evidence on reversible up-regulation by typical neuroleptics. Journal of Neurochemistry 1998, 71:2454-2464.
130. Standaert D.G., Landwehrmeyer G.B., Kerner J.A., Penney J.B., Young A.B. Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. Molecular Brain Research 1996, 42:89-102.
131. Stone J.M., Dietrich C., Edden R., Mehta M.A., De Simoni S., Reed L.J., et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine- induced psychopathology. Molecular Psychiatry 2012, 17:664-665.
132. Tatard-Leitman V.M., Jutzeler C.R., Suh J., Saunders J.A., Billingslea E.N., Morita S., et al. Pyramidal cell selective ablation of N-methyl-d-aspartate receptor 1 causes increase in cellular and network excitability. Biol. Psychiatry 2015, 77:556-568.
133. The Cochrane Collaboration Review manager (RevMan) [computer program] 2014, The Nordic Cochrane Centre, Copenhagen. 5.3 ed.
134. Tikhonravov D., Neuvonen T., Pertovaara A., Savioja K., Ruusuvirta T., Naatanen R., et al. Effects of an NMDA-receptor antagonist MK-801 on an MMN-like response recorded in anesthetized rats. Brain Research 2008, 1203:97-102.
135. Todd J., Harms L., Schall U., Michie P.T. Mismatch negativity: translating the potential. Frontiers in Psychiatry 2013, 4(171).
136. Todd J., Michie P.T., Schall U., Karayanidis F., Yabe H., Naatanen R. Deviant matters: duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. Biol. Psychiatry 2008, 63:58-64.
137. Todd J., Michie P.T., Schall U., Ward P.B., Catts S.V. Mismatch negativity (MMN) reduction in schizophrenia-impaired prediction-error generation, estimation or salience?. International Journal of Psychophysiology 2012, 83:222-231.
138. Toro C., Deakin J.F.W. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophrenia Research 2005, 80:323-330.
139. Tuominen H.J., Tiihonen J., Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 2005, 72:225-234.
140. Umbricht D., Javitt D., Novak G., Bates J., Pollack S., Lieberman J., et al. Effects of risperidone on auditory event-related potentials in schizophrenia. International Journal of Neuropsychopharmacology 1999, 2:299-304.
141. Umbricht D., Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophrenia Research 2005, 76:1-23.
142. Umbricht D., Schmid L., Koller R., Vollenweider F.X., Hell D., Javitt D.C. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers-implications for models of cognitive deficits in schizophrenia. Archives of General Psychiatry 2000, 57:1139-1147.
143. Wacongne C., Changeux J.P., Dehaene S. A neuronal model of predictive coding accounting for the mismatch negativity. Journal of Neuroscience 2012, 32:3665-3678.
144. Weickert C.S., Fung S.J., Catts V.S., Schofield P.R., Allen K.M., Moore L.T., et al. Molecular evidence of N-methyl-d-aspartate receptor hypofunction in schizophrenia. Molecular Psychiatry 2013, 18:1185-1192.
145. Womelsdorf T., Valiante T.A., Sahin N.T., Miller K.J., Tiesinga P. Dynamic circuit motifs underlying rhythmic gain control, gating and integration. Nature Neuroscience 2014, 17:1031-1039.
146. Woo T.U.W., Shrestha K., Lamb D., Minns M.M., Benes F.M. N-methyl-d-aspartate receptor and calbindin-containing neurons in the anterior cingulate cortex in schizophrenia and bipolar disorder. Biol. Psychiatry 2008, 64:803-809.
147. Woo T.U.W., Walsh J.P., Benes F.M. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-d-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Archives of General Psychiatry 2004, 61:649-657.
148. Wu J.C., Buchsbaum M.S., Potkin S.G., Wolf M.J., Bunney W.E. Positron emission tomography study of phencyclidine users. Schizophrenia Research 1991, 4:415.
149. Wynn J.K., Sugar C., Horan W.P., Kern R., Green M.F. Mismatch negativity, social cognition, and functioning in schizophrenia patients. Biol. Psychiatry 2010, 67:940-947.
150. Zhang Z., Sun Q.Q. Development of NMDA NR2 subunits and their roles in critical period maturation of neocortical GABAergic interneurons. Developmental Neurobiology 2011, 71:221-245.